Exacerbation Rate Reduction with Mepolizumab, Stratified by Maintenance OCS Use and Eosinophil Levels. A Post-Hoc Analysis of DREAM and MENSA Studies.
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
6
References
0
Citations
NaN
KQI